4Bio Ventures — 2025 Investments
1 investments dated 2025 · listed companies and verified rows first · show all
NV Therapeuticsnvtx.bioinMar 2025SEC filingmedium confidence
Novaptix develops non-viral gene writing technology intended to support the development and scaling of gene therapies.
BiotechDeep TechMedical DevicesBerkeley, US
Kevin Holden(Executive Officer, Director, Promoter)
BoardAudrey Kozlov(Director)Daniel Dever(Director)
Board seatDmitry Kuzmin· per SEC Form D · $7.5M raise · filed Mar 2025
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.